Jaehyuk Choi, M.D., Ph.D. Titles and Appointments Inaugural Director of the Center for Cellular Therapies and Cancer Immunology in the Harold C. Simmons Comprehensive Cancer Center | Vice Chair for Translational Research and Innovation in the Department of Dermatology Professor Endowed Title Scheryle Simmons Patigian Distinguished Chair in Cancer Immunobiology School Medical School Department Dermatology | Harold C. Simmons Comprehensive Cancer Center Graduate Programs Cancer Biology, Immunology Biography Jaehyuk Choi, M.D., Ph.D. is a Professor of Dermatology and of the Simmons Comprehensive Cancer Center at UTSW. He is the inaugural director of the Center for Cellular Therapies and Cancer Immunology. An NIH-funded physician scientist, Dr. Choi has contributed to our understanding of the cellular and genetic bases of cutaneous lymphomas, reporting the first or the largest series of cutaneous CD4+ (MF, Sezary, and ATL), CD8+, CD4-CD8-, gamma delta, and multiple B cell lymphomas (diffuse large B cell and follicular). These studies have been published in Nature, Nature Cancer, Blood, amongst other journals. Collectively, they have identified clinically actionable biomarkers and therapeutic targets. His work has been recognized with the NIH New Innovator Award, the Damon Runyon Clinical Investigator Award, and the Mark Foundation Emerging Leader Award amongst others. Education Harvard University, AB, June 1998, Biochemistry Summa Cum Laude Yale University, M.D., Ph.D., June 2006, Immunology, Alpha Omega Alpha, Cum Laude, M.D., Ph.D. Thesis of the Year Post Graduate Training Yale University School of Medicine, 2006-2010, Dermatology Residency Yale University School of Medicine, 2009-2015, Post-doctoral Fellow Education Medical School Yale University School of Medicine Residency Yale New Haven Hospital (2007), Internal Medicine Fellowship Yale New Haven Hospital (2010), Dermatology Publications Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinib Torres-Cabala CA, Yescas JA, Zhang Y, Huen A, Sumit G, Tefft K, Tang G, Curry JL, Gunther J, Dabaja B, Iyer S, Miranda RN, Choi J, Nardi V Blood Advances 2025 Apr 9 1786-1790 Addiction of primary cutaneous γδ T cell lymphomas to JAK/STAT signaling Zhang Y, Yescas JA, Tefft K, Ng S, Qiu K, Wang EB, Akhtar S, Walker A, Welborn M, Zaiac M, Guitart J, Qureshi AM, Kim YH, Khodadoust MS, Issa NT, Choi J Journal of Clinical Investigation 2025 Apr 135 A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas Merrill MH, Redd RA, Fisher DC, Abramson JS, Barnes J, Choi J, Jacobson CA, Kim AI, Lunning MA, Jester HD, Jeter EL, McDonough MM, Armand P, Jacobsen ED Leukemia and Lymphoma 2025 66 1354-1357 Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations Myers CS, Williams E, Cornejo CB, Pongas G, Toomey NL, Sanches JA, Battistella M, Mo S, Pulitzer M, Moskaluk CA, Bhagat G, Ofori K, Davick JJ, Servitje O, Miyashiro D, Climent F, Ringbloom K, Duenas D, Law C, Zambrano SC, Malpica L, Beltran BE, Castro D, Barreto L, Brites C, Chapman JR, Choi J, Gru AA, Ramos JC Haematologica 2024 Dec 109 4021-4039 Inhibitory co-receptor Lag3 supports Foxp3+ regulatory T cell function by restraining Myc-dependent metabolic programming Kim D, Kim G, Yu R, Lee J, Kim S, Gleason MR, Qiu K, Montauti E, Wang LL, Fang D, Choi J, Chandel NS, Weinberg S, Min B Immunity 2024 Nov 57 2634-2650.e5 Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications Akaike T, Thakuria M, Silk AW, Hippe DS, Park SY, So NA, Maloney NJ, Gunnell L, Eschholz A, Kim EY, Sinha S, Hall ET, Bhatia S, Reddy S, Rodriguez AA, Aleshin A, Choi JS, Tsai KY, Yom SS, Yu SS, Choi J, Chandra S, Nghiem P, Zaba LC Journal of Clinical Oncology 2024 Sep 42 3151-3161 Preexisting Skin-Resident CD8 and γδ T-cell Circuits Mediate Immune Response in Merkel Cell Carcinoma and Predict Immunotherapy Efficacy Reinstein ZZ, Zhang Y, Ospina OE, Nichols MD, Chu VA, de Mingo Pulido A, Prieto K, Nguyen JV, Yin R, Segura CM, Usman A, Sell B, Ng S, de la Iglesia JV, Chandra S, Sosman JA, Cho RJ, Cheng JB, Ivanova E, Koralov SB, Slebos RJ, Chung CH, Khushalani NI, Messina JL, Sarnaik AA, Zager JS, Sondak VK, Vaske C, Kim S, Brohl AS, Mi X, Pierce BG, Wang X, Fridley BL, Tsai KY, Choi J Cancer discovery 2024 Sep 14 1631-1652 Correction to: Interferon subverts an AHR–JUN axis to promote CXCL13+ T cells in lupus (Nature, (2024), 631, 8022, (857-866), 10.1038/s41586-024-07627-2) Author Collaboration AM, Law C, Wacleche VS, Cao Y, Pillai A, Sowerby J, Hancock B, Horisberger A, Bracero S, Skidanova V, Li Z, Adejoorin I, Dillon E, Benque IJ, Nunez DP, Simmons DP, Keegan J, Chen L, Baker T, Brohawn PZ, Al-Mossawi H, Hao LY, Jones B, Rao N, Qu Y, Alves SE, Wyse A, Cordle A, Zhu Z, Zhang F, Xiao Q, Weisman M, Weisenfeld D, Weinand K, Wei K, Watts GF, Utz PJ, Tabechian D, Smith M, Slowikowski K, Singaraju A, Scheel-Toellner D, Seifert JA, Sakaue S, Sahbudin I, Rumker L, Robinson WH, Rivellese F, Ritchlin C, Reshef Y, Choi J Nature 2024 Aug 632 E6 Interferon subverts an AHR–JUN axis to promote CXCL13+ T cells in lupus Author Collaboration AM, Law C, Wacleche VS, Cao Y, Pillai A, Sowerby J, Hancock B, Horisberger A, Bracero S, Skidanova V, Li Z, Adejoorin I, Dillon E, Benque IJ, Nunez DP, Simmons DP, Keegan J, Chen L, Baker T, Brohawn PZ, Al-Mossawi H, Hao LY, Jones B, Rao N, Qu Y, Alves SE, Albrecht J, Anolik JH, Apruzzese W, Barnas JL, Bathon JM, Ben-Artzi A, Boyce BF, Boyle DL, Bridges SL, Bykerk VP, Campbell D, Ceponis A, Chicoine A, Curtis M, Deane KD, DiCarlo E, Donlin LT, Dunn P, Filer A, Carr H, Firestein GS, Forbess L, Geraldino-Pardilla L, Goodman SM, Choi J Nature 2024 Jul 631 857-866 KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes Assatova B, Willim R, Trevisani C, Haskett G, Kariya KM, Chopra K, Park SR, Tolstorukov MY, McCabe SM, Duffy J, Louissaint A, Huuhtanen J, Bhattacharya D, Mustjoki S, Koh MJ, Powers F, Morgan EA, Yang L, Pinckney B, Cotton MJ, Crabbe A, Ziemba JB, Brain I, Heavican-Foral TB, Iqbal J, Nemec R, Rider AB, Ford JG, Koh MJ, Scanlan N, Feith DJ, Loughran TP, Kim WS, Choi J, Roels J, Boehme L, Putteman T, Taghon T, Barnes JA, Johnson PC, Jacobsen ED, Greenberg SA, Weinstock DM, Jain S Clinical Cancer Research 2024 Jun 30 2514-2530 Results 1-10 of 85 1 2 3 4 5 Next Last Honors & Awards Chicago Biomedical ConsortiumNovel Immunotherapies for Pancreatic Cancer (2023-2023) NIH T32 AwardNorthwestern University Postdoctoral Training Program in Cutaneous Biology (2023-2025) Department of Defense IDEA AwardElucidating the Biology of Aggressive Kinase Fusion-Driven Cutaneous T- Cell Lymphomas (2022-2025) Mark Foundation Emerging Leader AwardExploiting Naturally Occurring Mutations to Engineer Next-Generation T Cell Therapies (2022-2025) Leukemia Lymphoma Society ScholarValidating Genomic Biomarkers of Aggressive Subtypes of CTCL (2021-2025) NIH R01 AwardMechanisms of Lymphomagenesis of Skin Resident Gamma Delta T Cells. (2021-2025) V Foundation Immuno-Oncology Translational Program AwardIdentifying Mechanisms of Resistance to Immunotherapy for Merkel Cell Carcinoma. (2021-2024) American Cancer Society-Research Scholar GrantValidating Genomic Biomarkers of Aggressive Subtypes of CTCL (2020-2024) Doris Duke Charitable Foundation COVID Bridge AwardValidating Genomic Biomarkers of CTCL (2020-2020) Lefkofksy AwardDesigning Novel Cellular Therapies for Intractable Cutaneous Lymphomas (2020-2022) Doris Duke Data Sharing AwardIdentifying the genetic basis of altered T cell receptor signaling in CTCL (2019-2020) National Comprehensive Cancer Network FoundationGenomic Determinants of Responses to Immunotherapy in MCC (2019-2021) Skin Biology and Disease Research Core Pilot and Feasibility AwardIdentifying and Characterizing Skin-Resident T cells (2019-2021) Doris Duke Clinical Research MentorshipIdentifying NF-KB Targets in CTCL (2018-2019) Chicago Region Physical Sciences Oncology CenterDefining the molecular consequences of isochromosomes on chromosome segregation and gene transcription. (2017-2018) NIH DP2 New Innovator AwardIdentifying Mechanisms Underlying T Cell Diversity (2017-2022) Northwestern University Clinical and Translational Sciences InstituteIdentifying targetable gene mutations in CBCL (2017-2018) Chicago Biomedical ConsortiumNovel single-cell analyses of tumor-specific T cells in MCC (2016-2018) Damon Runyon Clinical Investigator AwardValidating Genomic Biomarkers of CTCL (2016-2021) Doris Duke Clinical ScientistIdentifying the genetic basis of altered T cell receptor signaling in CTCL (2016-2019) Leukemia Research FoundationIdentification of the Drivers of Disease Progression in CTCL (2016-2017) Skin Cancer FoundationDevelopment of CTCL-Seq (2016-2017) American Cancer Society- Institutional Research GrantTargeting CD28 Mutations in CTCL (2015-2017) NIH K08 AwardThe Role of ZEB1 Mutations in CTCL (2015-2020) Yale SPORE in Skin Cancer Career Development AwardForward Genetic Screen to Identify Genes that Confer Resistance in Melanoma (2012-2014) Dermatology Foundation Career Development AwardForward Genetic Screen to Identify Genes that Confer Resistance in Melanoma (2011-2014) American Skin Association Research GrantForward Genetic Screen for Tumor Suppressors in Mouse Skin Using PiggyBac (2010-2011) Dermatology Foundation Investigator Research FellowshipForward Genetic Screen for Tumor Suppressors in Mouse Skin Using PiggyBac (2010-2011) Professional Associations/Affiliations Dermatology Foundation Medical and Scientific Review Committee (2022-2025)
